Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Stock Moving News
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(101)
•••
Comment by AntibeTribeon Apr 09, 2021 8:18am
88 Views
Post# 32965261

RE:RE:Stock Moving News

RE:RE:Stock Moving News
Inthepez wrote:
Did the clown re-enter and getting fomo? 
Looking forward to the next you sell and starting bashing again. 
Ill be sure to chronicle your posts and time stamp them for all to see. Lol! 

Duster340 wrote: on the way soon folks.

*AME Study results (my guess before month end)


*Updated progress of the developement of new molecules (could be anytime)


*Evolution Summit may/11-13th

just a few near term catalysts  that will move the stock price higher
glta




TBH Pez, it's really not even worth your time or effort to reply to anything he says. Anyone that visits this board with regularity will either have him blocked or know better then to feed this particular troll. Ignore him like the annoying child that he is. Or don't. Whatever. < br/="">*sets up sign*< br/=""> DON'T FEED THE TROLLS. (He's prob Russian)
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities